Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Gaurav Syal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Pouchitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA.
- Atrius Health, Boston, MA, USA.
- Karsh Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
- Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
ORCID-Profile: Gaurav Syal, Gil Y Melmed
Zitieren
APA
Syal, G., Mishkin, D. S., Banty, A., Lee, S., Fontelera, N., Hampton, M., Ziring, D., Fleshner, P. R., & Melmed, G. Y. (2024). Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad191
Vancouver
Syal G, Mishkin DS, Banty A, Lee S, Fontelera N, Hampton M, et al. Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad191
BibTeX
@article{Syal2024,
author = {Syal, Gaurav and Mishkin, Daniel S and Banty, Andrea and Lee, Susie and Fontelera, Norma and Hampton, Melissa and Ziring, David and Fleshner, Phillip R and Melmed, Gil Y},
title = {Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad191}
}
EUVIMED